Robert A. Hazlitt

CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss

Tal Teitz, Jie Fang, Asli N. Goktug et al. · The Journal of Experimental Medicine · 2018 · 103 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +17

AZD5438-PROTAC: A selective CDK2 degrader that protects against cisplatin- and noise-induced hearing loss

Santanu Hati, Marisa Zallocchi, Robert A. Hazlitt et al. · European Journal of Medicinal Chemistry · 2021 · 42 citations · Full text

Medicine, Audiology, Molecular Biology +14

Development of Second-Generation CDK2 Inhibitors for the Prevention of Cisplatin-Induced Hearing Loss

Robert A. Hazlitt, Tal Teitz, Justine D. Bonga et al. · Journal of Medicinal Chemistry · 2018 · 37 citations · Full text

Medicine, Oncology, Pharmacology +16

Conversion of methyl ketones and methyl sulfones into α-deutero-α,α-difluoromethyl ketones and α-deutero-α,α-difluoromethyl sulfones in three synthetic steps

Munia F. Sowaileh, Changho Han, Robert A. Hazlitt et al. · Tetrahedron Letters · 2016 · 26 citations · Full text

Natural Sciences, Biochemistry, Chemistry +3

Optimized synthesis of a pentafluoro- gem -diol and conversion to a CF2Br -glucopyranose through trifluoroacetate-release and halogenation

Robert A. Hazlitt, Jinu P. John, Que-Lynn Tran et al. · Tetrahedron Letters · 2016 · 14 citations

Pharmacy, Chemistry, Carbohydrate Chemistry +2